Close Menu

Pressure BioSciences

The platform combines Leica's laser microdissection tool and PBI's pressure cycling tech to enable better extraction and digestion of proteins from biopsies.

The company also disclosed that it dropped plans for a $12.5 million offering of stock and warrants following a recent reverse stock split.

The one-for-30 reverse split is intended to increase the price of the company's stock, enabling it to satisfy the Nasdaq's initial listing requirements.

The revenue increase was driven by growth in sales of both instrument systems and consumables.

A 55 percent increase in the company's Q4 products and services revenues was softened by a 58 percent decrease in its grant revenues.

The company's Barocycler 2320Extreme is now available to the European biopharma market.

The decline resulted from a drop in grant revenues, which more than offset an increase in instrument sales.

The revenue increase was driven by strong growth in instrument and consumable sales, which more than offset declining grant revenue.

The company said instrument sales rose 41 percent during the quarter, while sales of consumables rose 11 percent.

The researchers found that adding PBI's MicroPestle tool to a conventional pressure cycling workflow yielded between 20 and 40 percent more peptides.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.